Scolaris Content Display Scolaris Content Display

Screening for breast cancer with mammography

This is not the most recent version

Collapse all Expand all

Abstract

Background

Mammographic screening for breast cancer is controversial, as reflected in greatly varying national policies.

Objectives

To assess the effect of screening for breast cancer with mammography on mortality and morbidity.

Search methods

MEDLINE (16 May 2000), The Cochrane Breast Cancer Group's trial register (24 Jan 2000) and reference lists. Letters, abstracts and unpublished trials. Authors were contacted.

Selection criteria

Randomised trials comparing mammographic screening with no mammographic screening.

Data collection and analysis

Data were extracted by both authors independently.

Main results

Seven completed and eligible trials involving half a million women were identified. The two best trials provided medium‐quality data and, when combined, yield a relative risk for overall mortality of 1.00 (95% CI 0.96‐1.05) after 13 years. However, the trials are underpowered for all‐cause mortality, and confidence intervals include a possible worthwhile effect as well as a possible detrimental effect. If data from all eligible trials (excluding flawed studies) are considered then the relative risk for overall mortality after 13 years is 1.01 (95% CI 0.99‐1.03).

The best trials failed to show a significant reduction in breast cancer mortality with a relative risk of 0.97 (95% CI 0.82‐1.14). If data from all eligible trials (excluding flawed studies) are considered then the relative risk for breast cancer mortality after 13 years is 0.80 (95% CI 0.71‐0.89). However, breast cancer mortality is considered to be an unreliable outcome and biased in favour of screening. Flaws are due to differential exclusion of women with breast cancer from analysis and differential misclassification of cause of death.

Authors' conclusions

The currently available reliable evidence does not show a survival benefit of mass screening for breast cancer (and the evidence is inconclusive for breast cancer mortality). Women, clinicians and policy makers should consider these findings carefully when they decide whether or not to attend or support screening programs.

PICOs

Population
Intervention
Comparison
Outcome

The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.

See more on using PICO in the Cochrane Handbook.

Plain language summary

Screening uses a test to check people who have no symptoms of a particular disease, in order to identify people who might have that disease. Mammography uses x‐ray to try to find early breast cancers before a lump can be felt. Many countries have introduced mammography for women aged 50‐69. This might allow breast cancer to be treated at an early stage where a cure is more likely. However, the review found that while several trials have been performed, most were of poor quality, and questions remain about the effectiveness of screening for lowering death rates due to breast cancer.